Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.98 USD | +1.09% | +7.56% | +0.81% |
16/07 | Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation | MT |
18/06 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.81% | 260.68Cr | |
+25.83% | 4.66TCr | |
+45.38% | 4.17TCr | |
+0.69% | 4.12TCr | |
+30.52% | 3.24TCr | |
+22.30% | 2.82TCr | |
-6.35% | 2.81TCr | |
+49.25% | 1.45TCr | |
+49.18% | 1.37TCr | |
+3.45% | 1.22TCr |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- SVB Securities Adjusts Celldex Therapeutics' Price Target to $64 From $68, Keeps Outperform Rating